|
11 Aug 2020 |
SAB Biotherapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of SAB-185 for the Treatment and Prevention of COVID-19
|
|
11 Aug 2020 |
Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study
|
|
11 Aug 2020 |
Byondis Initiates Phase I Study of Antibody-Drug Conjugate SYD1875
|
|
11 Aug 2020 |
Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis
|
|
11 Aug 2020 |
Fulcrum Therapeutics Announces Interim Analysis Data from its ReDUX4 Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)
|
|
11 Aug 2020 |
Verrica Pharmaceuticals Licenses LTX-315, A First-in-Class Oncolytic Peptide Based Immunotherapy, from Lytix Biopharma AS, for the Treatment of Dermatologic Oncology Indications
|
|
11 Aug 2020 |
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease and Grants Priority Review
|
|
11 Aug 2020 |
FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy
|
|
11 Aug 2020 |
Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis
|
|
11 Aug 2020 |
CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival
|
|
11 Aug 2020 |
CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers
|
|
11 Aug 2020 |
Bayer to Acquire UK-Based Biotech KaNDy Therapeutics Ltd.
|
|
11 Aug 2020 |
Ligand to Acquire Pfenex Inc.
|
|
11 Aug 2020 |
Clearside Biomedical Announces U.S. FDA Acceptance of Investigational New Drug Application for CLS-AX (axitinib injectable suspension) Administered in Suprachoroidal Space
|
|
11 Aug 2020 |
Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD, Reports Recent Business Progress and Second Quarter 2020 Financial Results
|
|
10 Aug 2020 |
Vaxart Announces IND Filed for COVID-19 Vaccine
|
|
10 Aug 2020 |
GeneCure Biotechnologies launches first-in-human therapeutic vaccine to treat Covid-19 patients
|
|
10 Aug 2020 |
BIOQUAL Announces Publication in The New England Journal of Medicine of Non-Human Primate Preclinical Viral Challenge Study of an mRNA Vaccine Against COVID-19 (mRNA-1273)
|
|
10 Aug 2020 |
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury® (Remdesivir) for the Treatment of COVID-19
|
|
10 Aug 2020 |
Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection
|
